Looking for Lilly’s LY4086940? Its two registered trials, NCT06945419 and NCT07890376, are listed below. For what they test and what has not been disclosed, see the LY4086940 profile or our LY4086940 write-up.
5 registered trials, newest registry update first. Showing only trials linked to Kisspeptin-10.
| Trial | Compound | Phase | Status | Sponsor | Enrolled | Primary completion | Registry updated |
|---|---|---|---|---|---|---|---|
| Prolonged Pulsatile Kisspeptin Administration in Hypogonadotropic Hypogonadism NCT04648969 | Kisspeptin-10 | Phase 2 | Completed | Stephanie B. Seminara, MD | 18 | Aug 31, 2025 | Aug 26, 2026 |
| Kisspeptin Administration Subcutaneously to Patients With IHH NCT05896293 | Kisspeptin-10 | Phase 2 | Recruiting | Stephanie B. Seminara, MD | 36 | May 2028 | Jul 13, 2026 |
| Kisspeptin Administration Subcutaneously to Patients With Reproductive Disorders NCT05633966 | Kisspeptin-10 | Phase 1 | Completed | Stephanie B. Seminara, MD | 13 | Aug 31, 2025 | Oct 3, 2025 |
| Elucidating Kisspeptin Physiology by Blocking Kisspeptin Signaling NCT01438073 | Kisspeptin-10 | Phase 1 | Completed | Massachusetts General Hospital | 96 | Apr 2016 | Jul 11, 2022 |
| A Phase 2a Pharmacodynamic Study of TAK-448 in Participants With Hypogonadotropic Hypogonadism NCT02369796 | Kisspeptin-10 | Phase 2 | Terminated | Takeda | 15 | Oct 2015 | Mar 31, 2017 |
Data: ClinicalTrials.gov, U.S. National Library of Medicine. Registered trials only. This table does not report results or recommend anything.
